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Abstract
Genetic risk factors are believed to combine with environmental exposures and contribute to risk
of developing temporomandibular disorder (TMD). In this prospective cohort study, 2,737 people
without TMD were assessed for common genetic variation in 358 genes known to contribute to
nociceptive pathways, inflammation, and affective distress. During a median follow-up period of
2.8 years, 260 people developed first-onset TMD. Hazard ratios (HRs) were computed as
measures of association between 2,924 single nucleotide polymorphisms (SNPs) and TMD
incidence. After correction for multiple testing, no single SNP was significantly associated with
risk of onset TMD. However, several SNPs exceeded Bonferroni correction for multiple
comparison or false discovery rate thresholds (FDR=0.05, 0.1, or 0.2) for association with
intermediate phenotypes shown to be predictive of TMD onset. Non-specific orofacial symptoms
were associated with voltage-gated sodium channel, type 1 alpha subunit (SCN1A, rs6432860,
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p=2.77×10−5) and angiotensin-I converting enzyme 2 (ACE2, rs1514280, p=4.86×10−5), global
psychological symptoms with prostaglandin-endoperoxide synthase 1 (PTGS1, rs3842803,
p=2.79×10−6), stress and negative affectivity with amyloid-β (A4) precursor protein (APP,
rs466448, p=4.29×10−5), and heat pain temporal summation with multiple PDZ domain protein
(MPDZ, rs10809907, p=3.05×10−5). The use of intermediate phenotypes for complex pain
diseases revealed new genetic pathways influencing risk of TMD.
Keywords
temporomandibular disorders; genetic risk factors; incidence; chronic pain; intermediate
phenotypes
Introduction
Idiopathic pain disorders such as temporomandibular disorders (TMD) are heterogeneous in
presentation and multifactorial in etiology, 24 both of which may be due in part to genetic
influences. We have previously hypothesized that persistent pain conditions result from two
parallel domains of vulnerability, each comprised of a temporally-dependent mosaic of
subclinical traits. 16 The first domain, pain amplification, may arise due to injury/trauma,
pro-inflammatory physiological state, impaired pain regulatory mechanisms, or autonomic
dysregulation. The second domain, psychological distress, can manifest as somatization,
anxiety, depression, stress response, or catastrophizing. Each of these domains is modulated
by numerous biological processes and probably influenced by many genes.
Genetic risk factors likely play a role in the etiology of TMD, based on a twin study that
attributed 44% of variation in the occurrence of TMD to genetic inheritance. 73 Case-control
studies of TMD have reported associations with genes in the serotonergic pathway,
including serotonin transporter SLC6A4, 35,53 serotonin 2A receptor HTR2A, 49 and the
serotonin metabolic enzyme tryptophan hydroxylase 1 TPH. 21 Adrenergic mechanisms
have also been implicated, based on findings that polymorphisms in both the β2-adrenergic
receptor ADRB2 15 and catechol-O-methyltransferase COMT 14 are associated with TMD
risk. The high proportion of female TMD subjects in many studies has prompted
consideration of the estrogen receptor gene ESR1 as a strong candidate for association with
TMD, although with conflicting results. 37,40,42,59 Similarly, commonly occurring genetic
variants have been associated with fibromyalgia and chronic widespread pain, including
ADRB2, 36,75 COMT, 6,46,71 TAAR1, 66 HTR2A 47 and SLC6A4. 9,51 Other painful
conditions found to have genetic associations include headache, 64 irritable bowel
syndrome,61 vulvar vestibulitis, 34 and low back pain, 11,12,50,68.
In the first phase of the Orofacial Pain: Prospective Evaluation and Risk Assessment
(OPPERA) study, we assessed 358 candidate pain genes in a case-control study of 348
chronic TMD subjects and 1,612 TMD-free controls. 65 No SNPs were statistically
significantly associated with chronic TMD after correction for multiple testing, but findings
supported a contribution from candidate genes including HTR2A, COMT, glucocorticoid
receptor (NR3C1), calcium/calmodulin-dependent protein kinase type IV (CAMK4),
muscarinic cholinergic receptor (CHRM2), interferon-related developmental regulator 1
(IFRD1), and the G protein-coupled receptor kinase 5 (GRK5).
An alternative strategy for discovering genetic contributions to TMD is to investigate
genetic influences on intermediate phenotypes that contribute to TMD. The contribution of
genetic influences relative to environmental factors may be stronger for intermediate
phenotypes. Four criteria have been proposed for this approach 27 where the intermediate
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phenotype: (1) is associated with TMD in the population; (2) is heritable; (3) manifests in an
individual independent of active disease; and (4) co-segregates with TMD in families. Other
papers in this volume address the first criterion by identifying phenotypes that predicted risk
of developing first-onset TMD. The prospective cohort fulfills the third criterion because
each phenotype was assessed at enrollment, prior to development of TMD.
Here we present findings from the OPPERA prospective cohort study, in which people
without TMD at enrollment were followed for up to five years. One aim was to identify
genetic polymorphisms that predicted incidence of first-onset TMD. Twenty-three genes
belonging to major neurotransmitter systems were chosen as primary candidates; the
remaining set of 335 genes was considered a discovery panel. A second aim was to identify
SNPs that were associated with intermediate phenotypes that predicted TMD incidence.
Materials and Methods
Study setting and participants
The details of recruitment and characterization of the OPPERA prospective cohort have
been described fully elsewhere, 4 and are summarized here. A total of 3,263 initially pain-
free subjects were recruited by advertisements, emails, flyers and word-of-mouth between
May, 2006 and November, 2008. They were recruited from communities in and around
academic health centers at four US study sites: Baltimore MD, Buffalo NY, Chapel Hill NC,
and Gainesville FL. These subjects included both males and females of diverse racial and
ethnic backgrounds, and were aged 18–44 years at enrollment. Only subjects (n=2,737) who
returned at least one follow-up screening questionnaire were included in the prospective
study of first-onset TMD. For this subset of OPPERA subjects, the mean age at enrollment
was 27.1 years (standard deviation = 7.8 years); 1,630 were female and 1,107 were male
(female:male ratio = 1.5:1). Approximately half (n=1,612) of this prospective cohort sample
was used previously in the OPPERA baseline case-control study of chronic TMD. 65 These
subjects, enrolled without TMD at baseline, were considered controls who were contrasted
with 185 subjects who had examiner-verified chronic TMD (i.e., “cases”). None of the
chronic TMD cases from that study were used in any analysis described in the present
prospective study of first-onset TMD.
Ethical conduct of research with humans
The OPPERA study was reviewed and approved by institutional review boards at each of
the four study sites and at the data coordinating center, Battelle Memorial Institute.
Participants verbally agreed to a screening interview done by telephone and provided
informed, signed consent for all other study procedures, including blood draw and genetic
analysis.
Genotyping
This paper focuses on genetic variants assessed at baseline that have been described in detail
elsewhere 65 and summarized here.
At enrollment, whole blood was collected by venipuncture from study participants who
provided consent for genotyping. Blood was collected into 5mL EDTA containing
polyethylene vacutainers, which were stored at −80ºC. Genomic DNA was purified utilizing
protocols based on Qiagen™ Extraction Kits at Cogenics, Inc. (now Integrated Laboratory
Systems, Morrisville, NC).
Samples were genotyped using the Algynomics (Chapel Hill, NC) Pain Research Panel, 66 a
dedicated chip-based platform utilizing the Affymetrix MegAllele technology. The panel
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assesses 3295 single nucleotide polymorphisms (SNPs) representing 358 genes known to be
involved in systems relevant to pain perception (complete list provided through http://
www.algynomics.com/pain-research-panel.html). The panel includes genes putatively
involved in intermediate processes underlying TMD, such as nociceptive transmission,
inflammation, and mood and affect. The SNPs selected for the panel prioritize functional
variants such as those that code for non-synonymous changes or result in differences in
expression or alternative splicing, while others were selected as representative markers of
regions with high linkage disequilibrium (LD), containing many correlated SNPs that are
inherited in blocks, in order to “tag” untyped variation.
Twenty-three genes (Supplemental Table 1) were chosen a priori as “first tier” candidate
genes, and, as described previously, 65 the probability of type I error was adjusted to account
for tests of their 211 SNPs in the analysis reported below. Quality assessment of Pain
Research Panel genotypes was performed using PLINK v.1.07 (Broad Institute, Cambridge
MA) 57 as previously described. 65 An identity-by-state analysis was performed using
principal components analysis (PCA) on the genotypes to cluster individuals according to
racial heritage. The first two principal components (eigenvectors) were retained for use as
covariates representing racial background in the association testing, in order to adjust for
population stratification. 56 Genotyping results were returned for 3221 unique samples,
which included enrollees in the prospective cohort study as well as cases for the case-control
study. The overall genotyping call rate was 99.1% and repeated sample concordance was
99.8%.
Phenotypic assessment
At three-monthly intervals after enrollment, study participants were asked to complete a
screening questionnaire that asked about TMD pain symptoms. 4 Those reporting symptoms
were invited to study clinics for a follow-up examination that determined presence or
absence painful TMD using OPPERA’s implementation of the research diagnostic criteria
for TMD.18 Specifically, the 260 incident cases satisfied two criteria for TMD: (1)
symptoms of orofacial pain reported for ≥5 days/month; and (2) examiner findings of TMD
myalgia, arthralgia, or both. For descriptive purposes, the rate of first-onset TMD was
calculated as the number of people with first-onset TMD divided by sum of follow-up
intervals.
A large number of potential risk factors for onset TMD were evaluated in OPPERA,
including measures related to clinical symptoms, psychosocial profile, somatic sensitivity,
and autonomic response. Given the large number of raw and derived variables assessed in
OPPERA subjects at enrollment, we narrowed our selection of phenotypes for genetic
analysis to reduce the burden of multiple testing. For measures of psychological status and
experimental pain sensitivity, we used PCA to recalculate factor scores first described in our
baseline case-control study.23,28 This reduced the large number of raw variables measured in
each domain, thereby mitigating the number of tests requiring Bonferroni adjustment and
producing more stable measures of the underlying construct compared to individual
measures. The PCA findings for this prospective cohort study are described elsewhere in
this supplement.25,29 . Furthermore, we designated as intermediate phenotypes only those
measures associated with first-onset TMD in our initially TMD-free subjects, following the
definition of Gottesman et al.27 Using these criteria, we selected eight characteristics as
intermediate phenotypes for this analysis, listed here with their respective univariate effect
on the incidence rate of TMD (hazard ratio, or HR, adjusted for site and demographic
variables). Dependent variables for the intermediate phenotypes taken from the clinical
measures52,62 were: (1) the number of comorbid health conditions (0, 1 or ≥2, HR = 1.39 for
1 and HR = 2.87 for ≥2 comorbid health conditions); (2) the number of non-specific
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orofacial symptoms (0, 1–2 or ≥3, HR = 1.98 for 1–2 symptoms and HR = 2.89 for ≥3
symptoms), (3) global score of the Pittsburg Sleep Quality Index (PSQI, a continuous
variable, HR = 1.4). Tenderness at 10 separate masticatory muscle groups (temporalis,
masseter, posterior mandibular and submandibular, lateral pterygoid area, and
temporomandibular joint, both right and left sides) during examination procedures was also
associated with first-onset TMD. For the intermediate phenotype analysis, we created a
single summary variable by counting (4) the number of tender masticatory muscles for each
individual, which was itself a strong predictor of TMD incidence (continuous variable, HR =
1.33). Intermediate phenotypes derived from the battery of psychosocial measures25
included: (5) the principal component from factor analysis of psychosocial measures that
signified global psychological symptoms (continuous variable, HR = 1.37); and (6) the
principal component from factor analysis of psychosocial measures signifying stress and
negative affectivity (continuous variable, HR = 1.17); Intermediate phenotypes associated
with incident TMD from among the QST variables29 were: (7) the principal component
from factor analysis of QST measures signifying pressure pain thresholds (a continuous
measure, HR = 1.14); and (8) the principal component from factor analysis of QST measures
signifying heat pain temporal summation (but only in the lowest tertile of first-pulse
responders, see the accompanying paper29 for details; continuous variable, HR = 1.54).
Association with TMD incidence and intermediate phenotypes
To test hypotheses about associations between genetic variants and TMD incidence rate in
the 2,737 subjects with follow-up data, univariate hazard ratios were computed using Cox
proportional hazard regression as implemented in the R package GenABEL v. 1.5–1. 3
Hazard ratios with 95% confidence intervals (95% CI), assuming codominant effects of
genotype, were computed with adjustment for study site and the first two racial
eigenvectors. Alternate genetic models, including tests of dominant and recessive
inheritance, were also tested. To evaluate stratum-specific genetic effects, additional tests
were performed as above in males and females separately; and in Caucasians and African-
Americans separately (without adjustment by racial eigenvectors). For the intermediate
phenotypes, all subjects enrolled without TMD at baseline were included in analyses
(n=3,037 with phenotype and genotype data). Association tests assuming codominant effects
were performed by fitting a generalized linear model in R, in which the quantitative or
binary observed phenotype was the dependent variable. Effect size and direction were
estimated using beta coefficients for quantitative traits, and odds ratios (OR) for binary
traits, and stratum-specific tests were performed as above.
Because we tested a large number of SNPs and several intermediate phenotypes, it was
necessary to adjust our standard of statistical significance in order to maintain a desired
experiment-wide α=0.05. It is also important to weigh the risk of false positives against the
risk of false negative results (Type II errors), which are common in association studies that
use conservative adjustments (such as a Bonferroni correction) evaluating large numbers of
correlated markers with small effect sizes. We used the false discovery rate (FDR) method 8
to control the expected proportion of false positives among associations reported as
significant, adopting a threshold FDR of 0.2. This method balances the considerations of
retaining power to detect true associations after correction for multiple testing, while
acknowledging that some results considered significant will be false positives.
Results
TMD Incidence
The cohort of 2,737 initially TMD-free people was followed for a total of 7,404 person-
years (median = 2.8 years per person), during which time 260 people developed first-onset
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TMD, yielding an annual incidence rate of 3.5% of people per annum. Additional details
regarding the demographics of subjects followed in the prospective cohort and those with
acute TMD are provided in the methods article in the present supplement. 4
The quantile-quantile (Q-Q) plot (Fig. 1) of the distribution of observed –log(p-values) from
tests of association with TMD incidence did not differ markedly from the null distribution
(genomic control λ<1), suggesting that adjusting for covariates was adequate to minimize
the effects of population stratification and other potential sources of systematic bias.56
The results of the top 20 SNPs in the full set of SNPs are provided in Table 1. As indicated
by the Q-Q plot, no statistically significant associations were observed. There were also no
SNPs with a Bonferroni-corrected statistically significant association for TMD incidence
among Tier 1 genes (see Supplemental Table 2 for top SNPs, and Supplemental Fig. 1 for
Q-Q plot).
Intermediate Phenotype Association Results
We next assessed association between the SNP panel and intermediate phenotypes
predictive of TMD incidence. As described elsewhere in this Supplement, 25,29,52,62 a
number of measures relevant to domains of hypersensitivity and psychological distress were
evaluated prospectively for association with first-onset TMD, and those that were predictive
of TMD incidence were identified as intermediate phenotypes. These included four clinical
variables 52,62 (the number of comorbid health conditions, the number of non-specific
orofacial symptoms, the number of masticatory muscle groups painful during examination
procedures, and the global score of the PSQI); two factors derived from the PCA of
psychosocial measures 25 (global psychological symptoms and stress and negative
affectivity); and two factors from the PCA of QST variables 29 (pressure pain threshold and
heat pain temporal summation).
Results for tests of association between each SNP and each intermediate phenotype are
depicted in Q-Q plots (Fig. 2; Supplemental Fig. 2 shows additional plots for tests with no
results with FDR<0.2 and tested non-intermediate phenotypes; Supplemental Fig. 3 shows
Manhattan plots for all tested phenotypes). The results for Q-Q plots are presented with
FDR=0.05, 0.1, and 0.2 thresholds assessing deviation from the null distribution. Effect size
estimates (relative to the minor allele) and p-values for all results that exceeded the
FDR=0.02 threshold are provided in Table 2, for the full cohort and by strata.
Association tests were performed for four clinical intermediate phenotypes: 52,62 the number
of (1) comorbid health conditions, (2) non-specific orofacial symptoms, (3) and masticatory
muscle groups painful during examination procedures, and (4) the global score of the PSQI.
The strongest association was with non-specific orofacial symptoms, including jaw stiffness,
cramping, fatigue, pressure, soreness, and ache. 52 Three linked SNPs within the voltage-
gated sodium channel, type I, alpha subunit gene SCN1A approached the corrected
significance threshold for association, including a non-synonymous Ala->Thr polymorphism
(best SNP rs6432860, minor allele (MA) = A, p = 2.77×10−5, OR = 1.42, 95% CI 1.21–
1.68). Another strong association was observed at an intronic SNP in the angiotensin-I
converting enzyme 2 gene, ACE2 (rs1514280, MA = T, p = 4.86×10−5, OR = 1.32, 95% CI
1.15–1.51). No associations were observed beyond the FDR=0.2 threshold for the other
clinical measures.
Two psychological factors associated with incident TMD were tested for genetic
association: global psychological symptoms, which includes characteristics such as
somatization, anxiety, depression, hostility, and psychoticism; and stress and negative
affectivity, which represents measures of state and trait anxiety, perceived stress, and
Smith et al. Page 6













neuroticism. 25 The strongest association with global psychological symptoms, exceeding
Bonferroni-corrected significance, was a synonymous Pro-Pro SNP in the prostaglandin-
endoperoxide synthase 1 gene PTGS1 (rs3842803, MA = C, p = 2.79×10−6, beta = −0.22,
95% CI −0.31– −0.13). This SNP is rare in Caucasians (MAF < 0.01), but fairly common in
African-Americans (MAF = 0.24); the SNP remains strongly associated in African-
Americans alone (p = 3.45×10−4). One polymorphism was associated with the stress and
negative affectivity factor, a promoter region SNP near the amyloid precursor protein gene,
APP (rs466448, MA = A, p = 4.29×10−5, beta = 0.11, 95% CI 0.06 – 0.17).
The QST variables were summarized by five principal components, of which only two were
examined as intermediate phenotypes. 29 One SNP was associated with heat pain temporal
summation in the lowest tertile of first-pulse responders,29 located in an intron of the
multiple PDZ domain protein MPDZ (rs10809907, MA = C, p = 3.05×10−5, beta = 0.16,
95% CI 0.09 – 0.24). No SNPs were significantly associated with the pressure pain threshold
principal component.
Discussion
In this prospective study, we did not observe significant variation in TMD incidence
according to genetic polymorphisms from the panel of candidate genes. Although the cohort
was large, the relatively small number of people who developed TMD limited our power to
detect genetic effects of small size. Despite nominating a small “first-tier” panel of putative
genes, and statistical methods that guarded against type II error, the lack of observed
associations may have occurred for several reasons. While a genetic basis for chronic TMD
has been established, acute onset TMD may be determined in large part by environmental
factors, such as trauma, infection, or stress, and only a subset of acute TMD cases will
become chronic. 19 Likewise, the causes of first-onset TMD may be more heterogeneous
than for chronic TMD. If so, genetic variants may be more readily discovered by clustering
cases of first-onset TMD into groups with similar pathophysiology, and therefore
hypothetically similar genetic determinants. Replication of suggestively associated SNPs in
a second independent cohort, which this study lacks, would be necessary to provide
additional evidence of genetic determination of onset TMD. To further explore the role of
common genomic variation in TMD, the OPPERA group has continued enrollment of
healthy and TMD subjects in preparation for a well-powered GWAS.
In contrast to the lack of results for onset TMD, we observed evidence for genetic
association in a number of pronociceptive intermediate phenotypes. The objective was to
find SNPs associated with intermediate phenotypes in our population limited to initially
TMD-free individuals, in order to find genetic loci that increase the risk of first-onset TMD.
We therefore did not use random sampling of the overall population, which narrows the
generalizability of these findings to people without TMD. The SNPs associated with
intermediate phenotypes possibly contribute to TMD incidence by increasing the risk of
developing these intermediate phenotypes. The implicated genes were derived from a pool
of pain candidate genes, each with a known physiological mechanism supporting its
relevance to development of TMD. However, there is still much yet to be understood
regarding the etiological pathway from genetic risk marker to pronociceptive domain
through to TMD onset.
Two genes, SCN1A and ACE2, were associated with the clinical measure of non-painful
orofacial symptoms, one of the predictors of TMD incidence. SCN1A encodes the alpha
subunit of the voltage-gated sodium channel Nav1.1, which is involved in the generation and
propagation of action potentials in sensory nerves. Mutations in SCN1A have been reported
to cause several types of epilepsy, especially those associated with febrile seizures, 74 and
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the gene has also been associated with short-term memory performance in a GWAS. 54
SCN1A rare mutations have been implicated in hereditary migraine, 17 although the degree
to which common variation in the gene affects normal sensation is unknown. Notably, this
gene belongs to the same family as SCN9A, which encodes the Nav1.7 channel and which
has been implicated in Mendelian disorders of spontaneous pain and insensitivity as well as
altered pain thresholds and risk of chronic pain disease. 58 Tight linkage disequilibrium
across the SCN1A locus resulted in several panel SNPs displaying evidence of association in
our study. The strongest associated SNP was rs6432860, a synonymous Val752Val
substitution in exon 13; another associated SNP (rs2298771) is a non-synonymous amino
acid substitution in exon 16 (rs2298771, Thr1056Ala) of unknown functional significance.
Determining the true effect variant responsible for differential perception of non-painful
orofacial symptoms is challenging, as numerous polymorphisms in tight LD within SCN1A
result in alterations in function or expression of the Nav1.1 channel. 54
The second gene associated with non-painful orofacial symptoms was ACE2, which codes
for the angiotensin I-converting enzyme 2. In accordance with the function of the renin-
angiotensin system in regulating blood pressure and fluid balance, numerous studies have
attributed genetic differences in risk of hypertension to variation in ACE2, 44 although no
studies have reported association with any pain or sensory symptoms. Angiotensin related
peptides have been posited as neurotransmitters in the periaqueductal gray 55 and other pain
relevant brain areas, where they modulate pro-and anti-nociceptive pathways. 10,45 In
addition to angiotensin-I, endogenous peptide substrates of ACE include bradykinin,
substance P, and opioids such as dynorphin and enkephalin, 20,72 suggesting the angiotensin
system plays a pivotal role underlying the relationship between blood pressure and pain
sensitivity. Pharmacological inhibition of ACE has been associated with increase in
nociceptive thresholds and tolerance 30 and risk of complex regional pain syndrome
(CRPS),13 suggesting lower levels of ACE activity due to genetic variation might underlie
altered somatic sensitivity. The ACE2 locus is located on the X chromosome, and the effect
of this SNP was stronger in males (OR = 1.35) than females (OR = 1.27). The SNP observed
in this study is located in an intron between exons 14 and 15, and is therefore likely to be a
tag of a nearby ungenotyped polymorphism of unknown function.
A SNP in the PTGS1 gene was associated with the psychosocial factor representing global
psychological symptoms, a significant and strong predictor of TMD incidence (HR=1.35),
and a discriminant of chronic TMD cases from controls. This gene encodes prostaglandin-
endoperoxide synthase 1, also known as COX-1, which catalyzes the production of
prostaglandins and is therefore pivotal in the regulation of neuronal sensitivity to pain and
the mediation of the inflammatory response. Polymorphisms in this gene result in resistance
to aspirin, 32 a COX inhibitor, and have been associated with risk of colorectal cancer 70 and
functional dyspepsia; 1 no genetic differences in pain sensitivity or risk of painful disease
have been reported. Prostaglandins are involved in an array of physiological processes,
suggesting that genetic factors that influence baseline or stimulated levels of prostaglandins
could alter somatic sensitivity and awareness of autonomic activity, nociception, vascular
muscle constriction or dilation, and gastrointestinal function. The SNP associated with
global psychological symptoms, rs3842803, is located in the terminal exon 11 of the gene,
where it results in a Pro503Pro synonymous change. The effect of this SNP was a decrease
in the global psychological symptoms in African-Americans carrying the minor allele,
indicating that the genetic effect is likely to inhibit prostaglandin production by attenuating
the activity of COX-1.
A second association with a psychosocial factor was observed between the stress and
negative affectivity factor and a SNP of the APP gene. Expressed by neurons, the amyloid-β
precursor protein is involved in synapse formation and neuronal plasticity; although its
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function is not yet fully understood, the expression of APP has been proposed as a
neuroprotective response to stress. 63 Proteolysis of APP results in β-amyloid, a major
component of plaques in the brain that have been associated with the development of
Alzheimer’s disease (AD). Risk of AD, especially familial or early-onset AD, has been
associated with polymorphisms of APP. 2,31 Cognitive ability and cognitive aging may also
be genetically modulated by the gene 33, suggesting APP polymorphism may underlie
deficits in the capacity to handle stressful life events in affected individuals. The associated
SNP, rs466448 (−1023T/C), is found in the promoter region of the gene, and has been
shown to increase expression levels of the protein. 41 The effect allele was associated with
increased stress factor scores in the OPPERA cohort, suggesting a genetic link between
higher levels of APP and higher perception of stress. 60,63,69
A single gene, MPDZ, was associated with a QST phenotype predictive of TMD onset, heat
pain temporal summation. This gene encodes a multiple PDZ domain protein, also known as
MUPP1, that functions as a scaffolding protein for several G protein-coupled receptors
involved in nociception and analgesia, including serotonergic 7 and GABAergic 5 receptors.
Polymorphisms in MPDZ have been associated with alcoholism, both in mice 22 and in
humans. 38 It has been suggested that MPDZ variation acts on alcohol dependence via the
NMDA-dependent AMPA trafficking cascade, 39 which as a regulator of glutamate-related
excitatory neurotransmission would be highly relevant to the phenotype of temporal
summation of thermal pain as well. The SNP associated with heat pain temporal summation
was located in an intron near exon 28 of the gene, and does not have any known functional
significance.
Though this study provides evidence for several genes contributing to the etiology of TMD,
it has a number of limitations that impact the interpretation of the findings. The power to
detect clinically meaningful hazard ratios for TMD was low. Power was generally high for
quantitative traits, but was still dependent on variables such as allele frequency and the
underlying effect size of the SNPs. The proportion of trait variance due to genetic factors is
poorly understood for TMD and the intermediate phenotypes, especially in a heterogeneous
sample such as OPPERA with many environmental sources of variance. The use of derived
variables such as factor scores, though intended to mitigate the problem of multiple testing,
makes it difficult to interpret differences in outcome measures due to genetic factors. It is
also possible that our selection of candidate genes based on known relevance to pain
pathways did not include the primary genes that contribute to risk of first-onset TMD.
Precedence for this comes from the large proportion of replicable associations discovered by
genome-wide association studies (GWAS) that are not found in or near loci of known
function or relevance to disease. 26 Another caveat to the interpretation of this study is that
we cannot generalize genetic association results for intermediate phenotypes to the general
population, as the study design did not include subjects with orofacial pain and was not a
true cross-section of the population. Finally, a statistical association between a gene and a
trait of interest does not fully explain the biological basis for that relationship; further
studies are required to characterize the functional consequences of these genetic
polymorphisms that result in alterations in nociceptive and psychological traits.
These genes demonstrating association should be examined in other cohorts, as the power in
this study alone was limited and meta-analytic methods have succeeded in confirming
numerous true genetic associations with effect sizes too small to detect in single low-
powered studies. 43,48,67,76 These genetic variants will be considered candidates to test
association in cohorts of acute and chronic TMD of more substantial statistical power which
are currently being collected. Furthermore, despite the large number of genes and variants
tested, we are unable to cover the full extent of genetic variability that may influence TMD
risk, such as rare variants, or genes not currently known to be relevant to pain. Instead, we
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have endeavored to test genes already implicated in pain processing, using a candidate gene
analysis. While this minimized the amount of multiple testing needed to assess the observed
risk factors, it will be important to extend these findings in other studies using GWAS and
other high-dimension methods. This study has shown the utility of considering intermediate
phenotypes, which are likely to be more strongly genetically determined and can be
measured in the full cohort to improve power. By dissecting the genetic architecture
underlying the physiological and behavioral domains of pain susceptibility, novel etiological
pathways and therapeutic approaches may be revealed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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This article reports the findings of a large candidate gene association study of first-onset
TMD and related intermediate phenotypes in the OPPERA Study. Although no genetic
markers predicted TMD onset, several genetic risk factors for clinical, psychological, and
sensory phenotypes associated with TMD onset were observed.
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Q-Q plot of all SNPs in the test of genetic association with TMD incidence
Black dots represent the observed –log10(p-value) for all SNPs passing quality control
criteria, compared with the expected values under the null distribution (gray diagonal line).
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Q-Q plots for intermediate phenotypes with SNPs associated at FDR < 0.2
Q-Q plots of all SNPs in four tests of genetic association with intermediate phenotypes of
first-onset TMD. Blue dots represent the observed –log10(p-value) for all SNPs passing
quality control criteria, compared with the expected values under the null distribution (gray
diagonal line). Additional colored lines are displayed above the gray line, indicating the
thresholds for the false discovery rate as indicated in the key.
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